Adagene Inc. ADAG · NASDAQ
$2.41 -1.23% (-$0.03)
Summary
24 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $127.9M against $6.09M.
- The price moves less than the market (beta 0.54).
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 6.2% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 74% a year over 5 years. Over the last 3 years it fell by 6.2% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $20.6M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 5
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $8.67 is 260% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2020By product
- Service 64%
- License 36%
By region
The company reports no revenue by region.
Service brings in 64% of revenue.
Segments in detail